Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

Pharmachronicles

Header Banner

Pharmachronicles

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • UGC-Cancelled-List of journals

  • NAAC stops accepting applications for accreditation from pharmacy colleges

  • Pursuing MPhil/PhD while working as a teacher will effect experience: UGC

  • Public notice by government of india ministry of health and family welfare

FDA Alerts
Home›FDA Alerts›FDA approved a new drug for seizures associated with Dravet Syndrome

FDA approved a new drug for seizures associated with Dravet Syndrome

By Ramoju kishore kumar
August 22, 2018
371
0
Share:

Recently FDA has approved DIACOMIT(stiripentol) for seizures associated with dravet syndrome in patients.

Dravet syndrome is a rare genetic condition that usually appears during the first year of life with prolonged fever-related seizures. Later, other types of seizures typically appear, and additionally, status epilepticus, a potentially life-threatening state of continuous seizure activity requiring emergency medical care, may occur. Children with Dravet syndrome typically experience poor development of language and motor skills, hyperactivity, and difficulty relating to others.

The efficacy of Diacomit was established in two multicenter placebo-controlled double-blind randomized studies (Study 1 and Study 2). Patients enrolled in the studies were required to be aged between 3 years and under 18 years with Dravet syndrome that was inadequately controlled with clobazam and valproate, and experiencing at least 4 generalized clonic or tonic-clonic seizures per month.

After a 1-month baseline period where patients continued to receive clobazam and valproate, they were then randomly selected to receive additional treatment with either Diacomit or placebo for a double-blind period of two months.

The primary efficacy endpoint for both studies was the responder rate – a responder being a patient who experienced more than 50% decrease in the frequency of seizures per month during the two month double-blind period compared to the one month baseline period.

In both studies, the responder rate was significantly greater for Diacomit than for placebo. In Study 1 (N=41), 71% of Diacomit patients (N=21) were responders, compared to 5% of patients taking the placebo (N=20), and 43% of patients reported no generalized clonic or tonic-clonic seizure during the duration of the study. In Study 2 (N=23), 67% of Diacomit patients (N=12) were responders, compared to 9.1% of patients taking the placebo (N=11), and 25% of patients reported no seizures.

The exact mechanism of action by which Diacomit exerts its anticonvulsant effect in humans is unknown, but possible actions include direct effects mediated through GABAA receptors and indirect effects involving inhibition of CYP450 activity.

Common side effects (occurring in at least 10% of Diacomit-treated patients) included somnolence (sleepiness and drowsiness), decreased appetite, agitation, ataxia (impaired coordination and balance), weight decreased, hypotonia (low muscle tone), nausea, tremor, dysarthria (difficulty speaking words; difficulty forming words during speech), and insomnia.

Diacomit will be available as oral capsules and powder for oral suspension, and prescriptions must be dispensed with a patient Medication Guide that describes important information about the drug’s uses and risks. As is true for many other drugs that treat epilepsy, the most serious risks include thoughts about suicide, attempts to commit suicide, feelings of agitation, new or worsening depression, aggression, and panic attacks.

TagschildrenDravet syndromeSeizures
Previous Article

Understanding About ANGINA PECTORIS

Next Article

Stem cell therapy for congestive heart failure

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0

Ramoju kishore kumar

Related articles More from author

  • Educational news

    National ethical guidelines for biomedical research involving children

    October 14, 2017
    By admin
  • BLOGS

    An innovative idea (Jerry the Bear) helps kids to manage diabetes.

    October 3, 2017
    By admin
  • Medical research

    Can Biological clock Affect Timing of Epileptic Seizures

    September 20, 2018
    By Ramoju kishore kumar
  • FDA AlertsMedical & HealthMedical research

    FDA approves a new clinical trial for non-healing wounds.

    October 28, 2017
    By admin
  • FDA Alerts

    FDA approves a new drug to treat malaria which could help millions.

    July 24, 2018
    By Sriram Nagarajan
  • FDA Alerts

    FDA recalls a anti hypertensive drug due to cancer concerns

    July 19, 2018
    By Ramoju kishore kumar

Leave a reply Cancel reply

You may interested

  • Uncategorized

    low levels of mean corpuscular hemoglobin concentration

  • BLOGS

    State-wise List of fake Universities as on June, 2017 as per UGC

  • Notifications

    Public notice by government of india ministry of health and family welfare

  • LATEST REVIEWS

  • TOP REVIEWS

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • October 20, 2020

    List of UGC Approved journals 2020

  • August 8, 2020

    LIST OF SCOPUS INDEXED JOURNALS JUNE 2020

  • June 8, 2020

    Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

  • June 4, 2020

    UGC-Cancelled-List of journals

  • June 1, 2020

    Saroj Group Of Hospitals restarts its complete operations – see major footfall in OPD consultation

Latest Comments

  • ActionScheduler
    on
    March 9, 2020
    action complete

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action created

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action started

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action complete

    wc_admin_unsnooze_admin_notes

  • ActionScheduler
    on
    March 9, 2020
    action created

    wc_admin_unsnooze_admin_notes

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • List of UGC Approved journals 2020

    By admin
    October 20, 2020
  • LIST OF SCOPUS INDEXED JOURNALS JUNE 2020

    By admin
    August 8, 2020
  • Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

    By Sriram Nagarajan
    June 8, 2020
  • UGC-Cancelled-List of journals

    By admin
    June 4, 2020
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Record Numbers of FDA‑Approved Drugs: Recent Trends

    By admin
    July 16, 2015
  • There make for Sixth that multiply blessed two divide creeping

    By admin
    July 16, 2015
  • FDA approved new drugs 2017

    By admin
    July 16, 2015
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action complete
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action created
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action started
  • ActionScheduler
    on
    March 9, 2020

    wc_admin_unsnooze_admin_notes

    action complete

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.